Cover Image
市場調查報告書

Cell Medica Limited的產品平台分析

Cell Medica Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 277782
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Cell Medica Limited的產品平台分析 Cell Medica Limited - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 23 Pages
簡介

Cell Medica Limited是總公司設置於英國的製藥企業,從事針對感染疾病及癌症的個別化細胞免疫療法藥的開發,製造,銷售。同時也在開發可製造抗原特異性T細胞的遵守GMP製造技術。

本報告提供Cell Medica Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Cell Medica Limited 基本資料

  • Cell Medica Limited 概要
  • 主要資訊
  • 企業資料

Cell Medica Limited :R&D概要

  • 主要的治療範圍

Cell Medica Limited :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Cell Medica Limited :開發中產品概況

  • 後期階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

Cell Medica Limited:藥物簡介

  • Cytovir-CM
  • CMD-003
  • Cytovir-ADV

Cell Medica Limited :開發平台分析

  • 各作用機制
  • 各分子類型

Cell Medica Limited :最新的開發平台資訊

Cell Medica Limited :開發暫停中的計劃

Cell Medica Limited :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06982CDB

Summary

Global Markets Direct's, 'Cell Medica Limited - Product Pipeline Review - 2015', provides an overview of the Cell Medica Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cell Medica Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cell Medica Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cell Medica Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cell Medica Limited's pipeline products

Reasons to buy

  • Evaluate Cell Medica Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cell Medica Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cell Medica Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cell Medica Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cell Medica Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cell Medica Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cell Medica Limited Snapshot
    • Cell Medica Limited Overview
    • Key Information
    • Key Facts
  • Cell Medica Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Cell Medica Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Cell Medica Limited - Pipeline Products Glance
    • Cell Medica Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Cell Medica Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Cell Medica Limited - Drug Profiles
    • Cytovir-CMV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CMD-003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cytovir-ADV
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cell Medica Limited - Pipeline Analysis
    • Cell Medica Limited - Pipeline Products by Route of Administration
    • Cell Medica Limited - Pipeline Products by Molecule Type
  • Cell Medica Limited - Recent Pipeline Updates
  • Cell Medica Limited - Dormant Projects
  • Cell Medica Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cell Medica Limited, Key Information
  • Cell Medica Limited, Key Facts
  • Cell Medica Limited - Pipeline by Indication, 2015
  • Cell Medica Limited - Pipeline by Stage of Development, 2015
  • Cell Medica Limited - Monotherapy Products in Pipeline, 2015
  • Cell Medica Limited - Phase III, 2015
  • Cell Medica Limited - Phase II, 2015
  • Cell Medica Limited - Phase I, 2015
  • Cell Medica Limited - Pipeline by Route of Administration, 2015
  • Cell Medica Limited - Pipeline by Molecule Type, 2015
  • Cell Medica Limited - Recent Pipeline Updates, 2015
  • Cell Medica Limited - Dormant Developmental Projects,2015

List of Figures

  • Cell Medica Limited - Pipeline by Top 10 Indication, 2015
  • Cell Medica Limited - Pipeline by Stage of Development, 2015
  • Cell Medica Limited - Monotherapy Products in Pipeline, 2015
  • Cell Medica Limited - Pipeline by Top 10 Route of Administration, 2015
  • Cell Medica Limited - Pipeline by Top 10 Molecule Type, 2015
Back to Top